
MEA Bladder Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Description
MEA Bladder Cancer Diagnostics Market - Industry Trends and Forecast to 2030
The Middle East and Africa bladder cancer diagnostics market is projected to register a substantial CAGR of 6.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Middle East and Africa Bladder Cancer Diagnostics Market, By Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and the rest of the Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Middle East and Africa bladder cancer diagnostics market are:
• Rising incidence of bladder cancer globally
• Rising awareness for the early diagnosis of bladder cancer
Market Players
Some of the key market players for the Middle East and Africa bladder cancer diagnostics market are listed below:
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Koninklijke Philips N.V.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• FUJIFILM Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• Siemens Healthcare GmbH
• BD
• Neusoft Corporation
• Abbott
• General Electric Company
• Hologic
• QIAGEN
• Cepheid.
• Ambu A/S
• Time Medical Holding.
• MinFound Medical Systems Co., Ltd.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
Table of Contents
160 Pages
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of The Middle East & Africa Bladder Cancer Diagnostics Market
- 1.4 Currency And Pricing
- 1.5 Limitations
- 1.6 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Dbmr Tripod Data Validation Model
- 2.5 Primary Interviews With Key Opinion Leaders
- 2.6 Multivariate Modelling
- 2.7 Test Type Segment Lifeline Curve
- 2.8 Market End User Coverage Grid
- 2.9 Dbmr Market Position Grid
- 2.10 Vendor Share Analysis
- 2.11 Secondary Sources
- 2.12 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Pestle Analysis
- 4.2 Porter's Five Forces Model
- 5 Middle East & Africa Bladder Cancer Diagnostics Market, Industry Insight
- 6 Regulatory Framework
- 7 Market Overview
- 7.1 Drivers
- 7.1.1 Rising Incidence Of Bladder Cancer Middle East & Africaly
- 7.1.2 Rising Awareness For The Early Diagnosis Of Bladder Cancer
- 7.1.3 Improved Imaging Techniques And Technology
- 7.1.4 Innovations In Drug Delivery To Bladder Cancer Cells
- 7.2 Restraints
- 7.2.1 High Cost Associated With Diagnosis And Treatment Of Bladder Cancer
- 7.2.2 Side Effects Of Bladder Cancer Treatment Drugs & Therapies
- 7.2.3 Late Diagnosis Of Bladder Cancer Resulting In Poor Prognosis
- 7.3 Opportunities
- 7.3.1 Increase In Diagnostic Procedures For Bladder Cancer
- 7.3.2 Rise In Healthcare Expenditure For Cancer Diagnosis
- 7.3.3 Increase In The Geriatric Population
- 7.4 Challenges
- 7.4.1 Ethical Challenges Faced During Bladder Cancer Testing
- 7.4.2 Stringent Regulations Among Bladder Cancer Diagnostics Tests And Procedures
- 8 Middle East & Africa Bladder Cancer Diagnostics Market, By Test Type
- 8.1 Overview
- 8.2 Cystoscopy
- 8.3 Urine Lab Test
- 8.3.1 Urine Cytology
- 8.3.2 Urinalysis
- 8.3.3 Urine Tumor Marker Test
- 8.3.4 Urine Culture
- 8.3.5 Others
- 8.4 Biopsy
- 8.5 Imaging Test
- 8.5.1 Magnetic Resonance Imaging (Mri) Scan
- 8.5.2 Computed Tomography (Ct) Scan
- 8.5.3 Ultrasound
- 8.5.4 Intravenous Pyelogram (Ivp)
- 8.6 Others
- 9 Middle East & Africa Bladder Cancer Diagnostics Market, By Stages
- 9.1 Overview
- 9.2 Stage Iv
- 9.3 Stage Iii
- 9.4 Stage Ii
- 9.5 Stage I
- 10 Middle East & Africa Bladder Cancer Diagnostics Market, By Cancer Type
- 10.1 Overview
- 10.2 Transitional Cell Bladder Cancer
- 10.3 Squamous Cell Bladder Cancer
- 10.4 Other Cancer Types
- 11 Middle East & Africa Bladder Cancer Diagnostics Market, By End User
- 11.1 Overview
- 11.2 Hospital
- 11.3 Diagnostic Imaging Centers
- 11.4 Cancer Research Institutes
- 11.5 Independent Diagnostic Laboratories
- 11.6 Associated Labs
- 12 Middle East & Africa Bladder Cancer Diagnostics Market, By Distribution Channel
- 12.1 Overview
- 12.2 Direct Tender
- 12.3 Retail Sales
- 13 Middle East & Africa Bladder Cancer Diagnostics Market, By Region
- 13.1 Middle East And Africa
- 13.1.1 South Africa
- 13.1.2 Saudi Arabia
- 13.1.3 U.A.E
- 13.1.4 Egypt
- 13.1.5 Israel
- 13.1.6 Rest Of Middle East And Africa
- 14 Middle East & Africa Bladder Cancer Diagnostics Market, Company Landscape
- 14.1 Company Share Analysis: Middle East & Africa
- 15 Swot Analysis
- 16 Middle East & Africa Bladder Cancer Diagnostics Market
- 16.1 F. Hoffmann- La Roche Ltd
- 16.1.1 Company Snapshot
- 16.1.2 Revenue Analysis
- 16.1.3 Company Share Analysis
- 16.1.4 Product Portfolio
- 16.1.5 Recent Developments
- 16.2 Merck Kgaa
- 16.2.1 Company Snapshot
- 16.2.2 Revenue Analysis
- 16.2.3 Company Share Analysis
- 16.2.4 Product Portfolio
- 16.2.5 Recent Development
- 16.3 Thermo Fisher Scientific Inc.
- 16.3.1 Company Snapshot
- 16.3.2 Revenue Analysis
- 16.3.3 Company Share Analysis
- 16.3.4 Product Portfolio
- 16.3.5 Recent Development
- 16.4 Koninlijke Philips N.V.
- 16.4.1 Company Snapshot
- 16.4.2 Revenue Analysis
- 16.4.3 Company Share Analysis
- 16.4.4 Product Portfolio
- 16.4.5 Recent Development
- 16.5 Bio-rad Laboratories, Inc.
- 16.5.1 Company Snapshot
- 16.5.2 Company Snapshot
- 16.5.3 Company Share Analysis
- 16.5.4 Product Portfolio
- 16.5.5 Recent Development
- 16.6 Abbott
- 16.6.1 Company Snapshot
- 16.6.2 Revenue Analysis
- 16.6.3 Product Portfolio
- 16.6.4 Recent Development
- 16.7 Agilent Technologies, Inc.
- 16.7.1 Company Snapshot
- 16.7.2 Revenue Analysis
- 16.7.3 Product Portfolio
- 16.7.4 Recent Development
- 16.8 Ambu A/S
- 16.8.1 Company Snapshot
- 16.8.2 Revenue Analysis
- 16.8.3 Product Portfolio
- 16.8.4 Recent Development
- 16.9 Bd
- 16.9.1 Company Snapshot
- 16.9.2 Revenue Analysis
- 16.9.3 Product Portfolio
- 16.9.4 Recent Development
- 16.10 Canon Medical Systems Corporation
- 16.10.1 Company Snapshot
- 16.10.2 Revenue Analysis
- 16.10.3 Product Portfolio
- 16.10.4 Recent Development
- 16.11 Cepheid
- 16.11.1 Company Snapshot
- 16.11.2 Revenue Analysis
- 16.11.3 Product Portfolio
- 16.11.4 Recent Developments
- 16.12 Fujifilm Corporation
- 16.12.1 Company Snapshot
- 16.12.2 Revenue Analysis
- 16.12.3 Product Portfolio
- 16.12.4 Recent Developments
- 16.13 General Electric Company
- 16.13.1 Company Snapshot
- 16.13.2 Revenue Analysis
- 16.13.3 Product Portfolio
- 16.13.4 Recent Developments
- 16.14 Hologic Inc.
- 16.14.1 Company Snapshot
- 16.14.2 Revenue Analysis
- 16.14.3 Product Portfolio
- 16.14.4 Recent Development
- 16.15 Illumina Inc
- 16.15.1 Company Snapshot
- 16.15.2 Revenue Analysis
- 16.15.3 Product Portfolio
- 16.15.4 Recent Developments
- 16.16 Minfound Medical Systems Co.,
- 16.16.1 Company Snapshot
- 16.16.2 Product Portfolio
- 16.16.3 Recent Developments
- 16.17 Neusoft Corporation
- 16.17.1 Company Snapshot
- 16.17.2 Company Snapshot
- 16.17.3 Product Portfolio
- 16.17.4 Recent Development
- 16.18 Qiagen
- 16.18.1 Company Snapshot
- 16.18.2 Revenue Analysis
- 16.18.3 Product Portfolio
- 16.18.4 Recent Development
- 16.19 Siemens Healthcare Gmbh
- 16.19.1 Company Snapshot
- 16.19.2 Revenue Analysis
- 16.19.3 Product Portfolio
- 16.19.4 Recent Development
- 16.20 Time Medical Holding.
- 16.20.1 Company Snapshot
- 16.20.2 Product Portfolio
- 16.20.3 Recent Developments
- 17 Questionnaire
- 18 Related Reports 160
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.